MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC

被引：6
|
作者：
Fang, Wenfeng [1 ]
Gan, Jiadi [1 ]
Hong, Shaodong [1 ]
Lu, Feng [2 ]
Zhang, Li [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
[2] Jinan Univ, Inst Life & Hlth Engn, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 07期
基金：
国家重点研发计划;
关键词：
CELL LUNG-CANCER; FUSION;
D O I：
10.1016/j.jtho.2019.02.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E148 / E151
页数：5
相关论文
共 50 条
  • [1] MPRIP-ALK, a novel ALK rearrangement that responds to ALK inhibitor in non-small-cell lung cancer
    Fang, Wenfeng
    Gan, Jiadi
    Lu, Feng
    Deng, Yangyang
    Chen, Liang
    Yang, Yunpeng
    Zhang, Li
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Novel Fusion Protein ALK-MPRIP Exhibits ALK Activation and Sensitivity to Crizotinib
    Shah, Namrata
    Teso, Kristina
    Zilli, Katie
    Menon, Smitha
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S691 - S692
  • [3] Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma
    Wang, Leiming
    Yao, Shuyang
    Teng, Lianghong
    Zhang, Weiwei
    Chen, Li
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : E44 - E46
  • [4] Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition
    Rao, Nisha
    Iwenofu, Hans
    Tang, Bingfeng
    Woyach, Jennifer
    Liebner, David A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (02): : 115 - 121
  • [5] Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH
    Hutarew, Georg
    Hauser-Kronberger, Cornelia
    Strasser, Felix
    Llenos, Ida C.
    Dietze, Otto
    HISTOPATHOLOGY, 2014, 65 (03) : 398 - 407
  • [6] CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer
    Zhang, M.
    Wang, Q.
    Ding, Y.
    Wang, G.
    Chu, Y.
    He, X.
    Wu, X.
    Shao, Y. W.
    Lu, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S800 - S800
  • [7] HIP1-ALK, A Novel ALK Fusion Variant that Responds to Crizotinib
    Fang, Douglas D.
    Zhang, Bin
    Gu, Qingyang
    Lira, Maruja
    Xu, Qiang
    Sun, Hongye
    Qian, Maoxiang
    Sheng, Weiqi
    Ozeck, Mark
    Wang, Zhenxiong
    Zhang, Cathy
    Chen, Xinsheng
    Chen, Kevin X.
    Li, Jian
    Chen, Shu-Hui
    Christensen, James
    Mao, Mao
    Chan, Chi-Chung
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) : 285 - 294
  • [8] CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer
    Zhang, Meiling
    Wang, Qian
    Ding, Yan
    Wang, Guoqun
    Chu, Yunqian
    He, Xiang
    Wu, Xue
    Shao, Yang W.
    Lu, Kaihua
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1792 - 1797
  • [9] A Novel Nonreciprocal/Reciprocal ALK Translocation Cause ALK plus in NSCLC
    Chen, Xianguo
    Xu, Bo
    Fu, Fangni
    Cai, Ke
    Yu, Zhaonan
    LUNG CANCER, 2021, 158 : 162 - 163
  • [10] ALK Inhibitors in the Treatment of ALK Positive NSCLC
    Khan, Muhammad
    Lin, Jie
    Liao, Guixiang
    Tian, Yunhong
    Liang, Yingying
    Li, Rong
    Liu, Mengzhong
    Yuan, Yawei
    FRONTIERS IN ONCOLOGY, 2019, 8
12345